FDA orphan drug designation: treatment of pulmonary arterial hypertension
All entries for: Regeneron Pharmaceuticals Inc.
November 10, 2025
Regeneron Pharmaceuticals Inc.
Orphan Drug Designation
Disease Area: Rare Diseases
FDA orphan drug designation: treatment of pulmonary arterial hypertension